Webb3 apr. 2024 · Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People’s Republic of China. Webb2 jan. 2024 · De raad van bestuur van Shanghai Junshi Biosciences Co., Ltd. kondigde aan dat de fase III klinische studie van VV116 tablet , een oraal nucleoside analoog anti-SARS-CoV-2 medicijn gezamenlijk... 4 januari 2024
Shanghai Junshi Biosciences Co., Ltd. gibt die Ergebnisse von drei ...
Webb11 apr. 2024 · Der Vorstand von Shanghai Junshi Biosciences Co, Ltd. gab bekannt, dass vor kurzem eine randomisierte, doppelblinde, placebokontrollierte, multizentrische … Webb3 dec. 2024 · Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - ENTERING INTO THE DRUG DEVELOPMENT AND LICENSE CONTRACT WITH HANGZHOU DAC MarketScreener Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make … china buffet hibbing menu
Shanghai Junshi Biosciences Co., Ltd.
Webb11 apr. 2024 · De raad van bestuur van Shanghai Junshi Biosciences Co, Ltd. kondigde aan dat onlangs een gerandomiseerde, dubbelblinde, placebogecontroleerde, multi-center … Webb20 jan. 2024 · Shanghai Junshi Biosciences Co., Ltd. and Wigen Biomedicine Technology Co., Ltd. Receives the Clinical Trial Approval Notice by National Medical Products Administration for Clinical Trial of the Aurora A Inhibitor WJ05129 Tablets MarketScreener Homepage Equities Hong Kong Hong Kong Stock Exchange Shanghai Junshi … Webb11 apr. 2024 · El consejo de administración de Shanghai Junshi Biosciences Co, Ltd. ha anunciado que recientemente se ha iniciado un estudio clínico de fase III, aleatorizado, … china buffet hendersonville nc